Brain Tumor Pathology最新文献

Biphasic high-grade cerebellar glioma with epithelial-like components: challenges in integrated diagnosis imposed by limited sampling. 具有上皮样成分的双期高级别小脑胶质瘤：有限采样带来的综合诊断挑战。

IF 3 3区医学

Brain Tumor Pathology Pub Date : 2026-04-29 DOI: 10.1007/s10014-026-00537-3

Yasuhide Takeuchi, Akihiko Sakata, Masahiro Tanji, Noritaka Sano, Shigeki Takada, Yohei Mineharu, Takanori Hirose, Kaishi Satomi, Junji Shibahara, Sachiko Minamiguchi, Hironori Haga, Yoshiki Arakawa

引用次数: 0

Correction: Comparative molecular profiles of distinct tumor components in recurrent tentorial meningioma after stereotactic radiosurgery: a case report implicating acquired aggressive alterations associated with WHO grade progression. 更正：立体定向放射手术后复发的幕脑膜瘤中不同肿瘤成分的比较分子谱：一个病例报告暗示与WHO级进展相关的获得性侵袭性改变。

IF 3 3区医学

Brain Tumor Pathology Pub Date : 2026-04-05 DOI: 10.1007/s10014-026-00535-5

Takeru Hirata, Yudai Hirano, Motoyuki Umekawa, Satoru Miyawaki, Yuki Shinya, Hirotaka Hasegawa, Yu Sakai, Noritaka Kudo, Daisuke Komura, Hiroto Katoh, Shumpei Ishikawa, Nobuhito Saito

引用次数: 0

Reappraisal of novel molecular parameters for meningioma grading by cIMPACT-NOW update 8 proposals. 通过cIMPACT-NOW重新评估脑膜瘤分级的新分子参数更新8项建议。

IF 3 3区医学

Brain Tumor Pathology Pub Date : 2026-04-01 Epub Date: 2025-10-01 DOI: 10.1007/s10014-025-00520-4

Kenta Masui, Asuka Komori, Shuhei Morita, Seiichiro Eguchi, Takakazu Kawamata, Mayu Kashiwagi-Hakozaki, Atsushi Kurata, Takashi Komori

引用次数: 0

Ataxin-2 as a candidate blood biomarker for estimating disease status in cases of suspected glioblastoma recurrence. Ataxin-2作为估计胶质母细胞瘤复发病例疾病状态的候选血液生物标志物。

IF 3 3区医学

Brain Tumor Pathology Pub Date : 2026-04-01 Epub Date: 2025-09-22 DOI: 10.1007/s10014-025-00517-z

Farida Garaeva, Riho Nakajima, Sho Tamai, Kensuke Tateishi, Akitake Mukasa, Shinji Kawabata, Hiroaki Nagashima, Manabu Natsumeda, Nozomi Hirai, Shota Tanaka, Shigeo Ohba, Nayuta Higa, Yoshiki Arakawa, Akihide Kondo, Hidehiro Kohzuki, Shinichiro Koizumi, Yutaka Fujioka, Tatsuya Abe, Hemragul Sabit, Masashi Kinoshita, Yasuo Uchida, Sumio Ohtsuki, Mitsutoshi Nakada

{"title":"Ataxin-2 as a candidate blood biomarker for estimating disease status in cases of suspected glioblastoma recurrence.","authors":"Farida Garaeva, Riho Nakajima, Sho Tamai, Kensuke Tateishi, Akitake Mukasa, Shinji Kawabata, Hiroaki Nagashima, Manabu Natsumeda, Nozomi Hirai, Shota Tanaka, Shigeo Ohba, Nayuta Higa, Yoshiki Arakawa, Akihide Kondo, Hidehiro Kohzuki, Shinichiro Koizumi, Yutaka Fujioka, Tatsuya Abe, Hemragul Sabit, Masashi Kinoshita, Yasuo Uchida, Sumio Ohtsuki, Mitsutoshi Nakada","doi":"10.1007/s10014-025-00517-z","DOIUrl":"10.1007/s10014-025-00517-z","url":null,"abstract":"Differentiating pseudoprogression (PsP) from recurrence in cases of glioblastoma (GBM) after chemoradiotherapy is challenging, with neuroimaging as the only non-invasive method. In this study, we aimed to identify a blood biomarker for precise disease monitoring and investigated the role of Ataxin-2 (ATXN2). Blood samples (n = 45) from patients with suspected recurrence, including eight with PSP, were analyzed. In addition, tumor tissue samples (n = 22), including those from seven patients who also provided blood samples, were examined. Protein levels were assessed using quantitative proteomics and ELISA. ATXN2 levels were measured via western blotting, and localization was determined through immunohistochemistry and immunocytochemistry. ATXN2 knockdown was performed in glioma cell lines to assess its effects on proliferation, migration, and invasion. Proteomics identified ATXN2 as a potential biomarker. ELISA showed significantly higher serum ATXN2 levels in recurrence than in PsP (p = 0.028). ATXN2 ≥ 11.0 ng/mL and ≥ 8 months post-chemoradiotherapy distinguished recurrence from PsP (AUC = 0.82, sensitivity = 67.6%, specificity = 87.5%). ATXN2 was highly expressed in GBM tissues, localized in neurons and glioma cells, and its knockdown enhanced proliferation, migration, and invasion via ERK phosphorylation. ATXN2, highly expressed in GBM, may serve as a potential blood biomarker for distinguishing PsP from recurrence.","PeriodicalId":9226,"journal":{"name":"Brain Tumor Pathology","volume":" ","pages":"43-55"},"PeriodicalIF":3.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13076406/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145112023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emergence of NEC features in corticotroph PitNETs: primary tumor, radiation-induced transformation, or metastasis? 皮质性PitNETs中NEC特征的出现：原发肿瘤、辐射诱导转化还是转移？

IF 3 3区医学

Brain Tumor Pathology Pub Date : 2026-04-01 Epub Date: 2025-09-03 DOI: 10.1007/s10014-025-00514-2

Naoko Inoshita, Hiroshi Nishioka, Noriaki Fukuhara, Keita Tatsushima, Akira Takeshita, Yasuhiro Takeuchi, Yutaka Takazawa, Naotetsu Kanamoto, Shozo Yamada

{"title":"Emergence of NEC features in corticotroph PitNETs: primary tumor, radiation-induced transformation, or metastasis?","authors":"Naoko Inoshita, Hiroshi Nishioka, Noriaki Fukuhara, Keita Tatsushima, Akira Takeshita, Yasuhiro Takeuchi, Yutaka Takazawa, Naotetsu Kanamoto, Shozo Yamada","doi":"10.1007/s10014-025-00514-2","DOIUrl":"10.1007/s10014-025-00514-2","url":null,"abstract":"Pituitary neuroendocrine tumors (PitNETs) are generally benign, but a small subset may demonstrate aggressive behavior or undergo malignant transformation. Neuroendocrine carcinoma (NEC), defined as a high-grade, poorly differentiated neuroendocrine neoplasm, is extremely rare in the pituitary, and its existence as a primary entity remains controversial. We report two cases of corticotroph PitNETs in female patients with Cushing disease, in which NEC components emerged several years after radiotherapy. Case 1 presented as an invasive macroadenoma with cavernous sinus invasion, and Case 2 as a 5 mm microadenoma. In both cases, recurrent tumors developed following subsequent radiotherapy. NEC components exhibited marked nuclear pleomorphism, necrosis, elevated Ki-67 indices, diffuse p53 expression, and loss or reduction of ACTH and TPIT expression. In Case 2, faint TPIT expression and discontinuous tumor growth within the sella raised the possibility of a metastatic NEC to the pituitary could not be excluded. These cases highlight the emergence of NEC features in corticotroph PitNETs, most likely as a result of post-radiotherapy transformation. However, due to faint TPIT expression and an unusual tumor distribution in Case 2, the possibility of a primary NEC or metastatic neuroendocrine neoplasm from another organ cannot be definitively excluded.","PeriodicalId":9226,"journal":{"name":"Brain Tumor Pathology","volume":" ","pages":"65-72"},"PeriodicalIF":3.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144943541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gyriform infiltration indicates tumor invasion burden of isocitrate dehydrogenase 1/2-wildtype gliomas. 异柠檬酸脱氢酶1/2野生型胶质瘤呈回状浸润，显示肿瘤侵袭负荷。

IF 3 3区医学

Brain Tumor Pathology Pub Date : 2026-04-01 Epub Date: 2025-10-09 DOI: 10.1007/s10014-025-00519-x

Hideyuki Arita, Kentaro Hirai, Mio Sakai, Tatsuya Hagioka, Koji Takano, Toru Umehara, Hidenori Yoshizawa, Yoshinori Kodama, Nobuo Kashiwagi, Katsuyuki Nakanishi, Yonehiro Kanemura

{"title":"Gyriform infiltration indicates tumor invasion burden of isocitrate dehydrogenase 1/2-wildtype gliomas.","authors":"Hideyuki Arita, Kentaro Hirai, Mio Sakai, Tatsuya Hagioka, Koji Takano, Toru Umehara, Hidenori Yoshizawa, Yoshinori Kodama, Nobuo Kashiwagi, Katsuyuki Nakanishi, Yonehiro Kanemura","doi":"10.1007/s10014-025-00519-x","DOIUrl":"10.1007/s10014-025-00519-x","url":null,"abstract":"Few robust radiological markers have been identified for predicting the molecular status of gliomas. Recently, gyriform infiltration (GI) has been identified as an imaging biomarker for molecular glioblastoma (mGBM). This study aimed to validate the diagnostic value of GI in predicting the molecular status of diffuse gliomas. Clinical data were retrospectively collected from patients treated at a single center. Their imaging findings, including GI and the status of molecular markers, including IDH TERT were compared. This study enrolled 137 patients, 16 (12%) of whom, were diagnosed with GI. The vast majority of GI-positive cases were IDH-wildtype (15/16 cases), including four mGBM and six histologically diagnosed glioblastoma cases. The diagnostic sensitivity and specificity of GI in predicting mGBM were 24% and 90%, respectively, and its diagnostic sensitivity and specificity in predicting IDH-wildtype gliomas were 15% and 97%, respectively. GI was also observed in IDH-wildtype gliomas without the molecular and histological features of glioblastoma. All five GI-positive cases with available 11C-methionine positron emission tomography scans showed increased tracer uptake in the GI area. GI is highly specific to IDH-wildtype gliomas. It delineates the tumor invasion burden and should be included as a target for local therapy, including radiation therapy.","PeriodicalId":9226,"journal":{"name":"Brain Tumor Pathology","volume":" ","pages":"56-64"},"PeriodicalIF":3.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Meningioma with trabecular architecture: a harbinger of BAP1 deficiency. 伴有小梁结构的脑膜瘤：BAP1缺乏的先兆。

IF 3 3区医学

Brain Tumor Pathology Pub Date : 2026-04-01 Epub Date: 2025-09-13 DOI: 10.1007/s10014-025-00516-0

Noriko Okuno, Takahiro Tomita, Takuya Akai, Satoshi Kuroda, Hiromasa Takakura, Kenichi Hirabayashi, Masakiyo Sasahara, Akira Kurose, Katsuyoshi Takata

{"title":"Meningioma with trabecular architecture: a harbinger of BAP1 deficiency.","authors":"Noriko Okuno, Takahiro Tomita, Takuya Akai, Satoshi Kuroda, Hiromasa Takakura, Kenichi Hirabayashi, Masakiyo Sasahara, Akira Kurose, Katsuyoshi Takata","doi":"10.1007/s10014-025-00516-0","DOIUrl":"10.1007/s10014-025-00516-0","url":null,"abstract":"BRCA (BReast CAncer gene)-associated protein 1 (BAP1) is a tumor suppressor protein encoded by the BAP1 gene. BAP1 mutations and the loss of BAP1 expression on immunohistochemistry are poor prognostic factors for meningiomas. These mutations have been previously reported in papillary and rhabdoid meningiomas. However, BAP1-deficient meningiomas with a trabecular architecture are rare, with only one previous report describing two cases. Here, we present the case of an 80-year-old male who experienced two recurrences of meningiomas over a 14-year period. The initial tumor exhibited a mixture of typical meningothelial meningioma and meningioma with trabecular architecture, whereas the second recurrence was almost entirely trabecular. Immunohistochemical analysis revealed a BAP1 deficiency. This case highlights the importance of the trabecular architecture as a histological pattern that may indicate BAP1 loss and poor prognosis. Given the potential for targeted therapies, further research is needed to establish this histological subtype as an independent entity with poor prognosis.","PeriodicalId":9226,"journal":{"name":"Brain Tumor Pathology","volume":" ","pages":"73-80"},"PeriodicalIF":3.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145051812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic significance of CDKN2A/B hemizygous deletion in IDH-mutant astrocytomas: a systematic review and meta-analysis. CDKN2A/B半合子缺失在idh突变星形细胞瘤中的预后意义：一项系统综述和荟萃分析。

IF 3 3区医学

Brain Tumor Pathology Pub Date : 2026-03-17 DOI: 10.1007/s10014-026-00536-4

Satoshi Nakasu, Shoichi Deguchi, Mónica Mezmezian, Koichi Mitsuya, Akifumi Notsu, Yoko Nakasu

引用次数: 0

Molecular analysis of a gliosarcoma with distinct oligodendroglioma and sarcomatous components ("Oligosarcoma"). 具有明显少突胶质细胞瘤和肉瘤成分的胶质肉瘤的分子分析（“少突肉瘤”）。

IF 3 3区医学

Brain Tumor Pathology Pub Date : 2026-03-15 DOI: 10.1007/s10014-026-00534-6

Shoh Sasaki, Maki Sakaguchi, Maiko Takeda, Yuji Nitta, Ryosuke Matsuda, Shohei Yokoyama, Akihiko Yoshizawa

引用次数: 0

Rare intracranial mesenchymal tumors with FET::CREB fusions: clinicopathologic spectrum of four cases with integrated molecular analysis and review of the literature. 罕见颅内间充质肿瘤伴FET::CREB融合：4例临床病理谱、综合分子分析及文献复习。